Impact of Nanomedicine in Women's Metastatic Breast Cancer

Abstract

Metastatic breast cancer is responsible for 90% of mortalities among women suffering from various types of breast cancers. Traditional cancer treatments such as chemotherapy and radiation therapy can cause significant side effects and may not be effective in many cases. However, recent advances in nanomedicine have shown great promise in the treatment of metastatic breast cancer. For example, nanomedicine demonstrated robust capacity in detection of metastatic cancers at early stages (i.e., before the metastatic cells leave the initial tumor site), which gives clinicians a timely option to change their treatment process (for example, instead of endocrine therapy they may use chemotherapy). Here recent advances in nanomedicine technology in the identification and treatment of metastatic breast cancers are reviewed.

Bioorthogonal “Click” Cycloadditions: A Toolkit for Modulating Polymers and Nanostructures in Living Systems

“…Polymers and nanostructures offer platforms that can operate safely in living systems [1][2][3], enabling the development of localized treatments with enhanced efficacy [4][5][6]. The advantage of these structures is the biocompatible scaffold combined with the possibility to host different types of therapeutic payloads [7][8][9].…”

V2C-Driven Nanodelivery Platform Potentiates Synergistic Breast Cancer Therapy

“…Several researchers have developed novel drug delivery systems to enhance tumor cell ablation and reduce side effects. 16 Studies have shown that nanocarrier-based Dox delivery can reduce drug protein interactions, achieve selective Dox accumulation at tumor sites, and alleviate systemic toxicity. 17 Thus, various Dox encapsulated nanomedicines have been developed for cancer treatment, including polymeric and liposomal nanoparticles as well as other inorganic nanosystems.…”

“…Recent advances in nanomedicine have shown great promise in the treatment of breast cancer. Several researchers have developed novel drug delivery systems to enhance tumor cell ablation and reduce side effects . Studies have shown that nanocarrier-based Dox delivery can reduce drug protein interactions, achieve selective Dox accumulation at tumor sites, and alleviate systemic toxicity .…”